Bristol Stock- Bristol-Myers and Eisai to jointly develop, market cancer drug
June 17 (Reuters) – Bristol-Myers Squibb Co BMY.N and Eisai Co on Thursday entered into an agreement to jointly develop and market an experimental cancer drug.
Bristol Myers will pay $650 million to Eisai and up to $2.45 billion in milestone payments.
(Reporting by Amruta Khandekar; Editing by Vinay Dwivedi)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.